{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Telomir Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"TELO"},"Address":{"label":"Address","value":"855 N WOLFE STREET,SUITE 601, BALTIMORE, 21205, United States"},"Phone":{"label":"Phone","value":"(737) 289-0835"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Its goal is to develop and commercialize new treatment options for age-related inflammatory conditions, with hemochromatosis as its initial clinical focus, and to thereafter expand the development of TELOMIR-1 to post-chemotherapy recovery as well as a broader range of other age-related inflammatory diseases and conditions such as osteoarthritis."},"CompanyUrl":{"label":"Company Url","value":"https://www.telomirpharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Erez Aminov","title":"Chairman & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}